11.JPG)
The iPSC Characterization Kit Market Size is predicted to grow at an 15.54 % CAGR during the forecast period for 2024-2031.
Key Industry Insights & Findings from the Report:
- The advent of the iPSC characterization kit market arose for technological innovation, regulatory support, and collaborative partnerships that propel stem cell research forward.
- The increasing applications in research and therapy are expected to drive this market’s growth.
- North America dominated the market and accounted for a global revenue share in 2023.
- One of the significant concerns restraining industry growth is the high cost associated with stem cell therapy.
A variety of delicate instruments are included in the iPSC characterization kit (induced pluripotent stem cell) for the phenotypic evaluation of the pluripotent state of human embryonic stem & induced pluripotent stem cells. Compared to embryonic stem cells (ESCs), induced pluripotent stem cells have several advantages, including avoiding the ethical concerns surrounding stem cells and offering the most significant degree of versatility for use in cell-based research. In recent years, these benefits have given induced pluripotent stem cells (iPSCs) a considerable boost, establishing a promising market for iPSC characterization kits. The strong pipeline for cell therapies derived from iPSCs and new iPSC applications is expected to accelerate market growth. Furthermore, the demand for iPSC characterization kits is expanding as a result of an increase in the prevalence of chronic diseases.
Additionally, induced pluripotent stem cells can be used to treat chronic diseases like diabetes, cancer, cancer, and heart disease, hence driving the iPSC characterization kit market. According to the Partnership to Fight Chronic Disorder (PFCD) survey, out of 133 million Americans, 45% of the population had at least one chronic disorder. In addition, it was calculated that chronic diseases account for 7 out of 10 deaths in the USA or roughly 1.7 million deaths, and that induced pluripotent stem cell therapy can prevent these deaths. Hence, the increased demand for induced pluripotent stem cell therapy is being driven by this surge in the prevalence of chronic disorders, which aids in the iPSC characterization kit market expansion.
Competitive Landscape
Some Major Key Players In The iPSC Characterization Kit Market:
- Merck KGaA,
- Takara Bio,
- Thermo Fisher Scientific,
- BD Biosciences,
- Applied StemCell,
- Amsbio,
- Bio-Techne,
- ALSTEM,
- STEMCELL Technologies,
- System Biosciences,
- Applied Biological Materials,
- Creative Bioarray,
- Elixirgen Scientific
- Miltenyi Biotec.
Market Segmentation:
The iPSC characterization kit market is segmented by type and application. Based on the type, the market is segmented into alkaline phosphatase staining assay, pluripotency markers (protein) and pluripotency markers (mRNA). Based on the application, the market is segmented into cancer research center, pathology laboratory, academic and research, contract research organizations and others.
Based On The Type, The Alkaline Phosphatase Staining Assay Category Is Accounted As A Major Contributor To The iPSC Characterization Kit Market.
The alkaline phosphatase staining assay category dominated the market in 2021. It is a stem cell imaging product used to stain pluripotent stem cells (PSCs) differentially. Over two hours, the dye diffuses out and acts as a cell-permeable fluorescent substrate for alkaline phosphatase (AP) that is non-toxic to cells. A high signal above the background enables the identification of pluripotent stem cells. Since it preserves stem cell viability, the alkaline phosphatase live stain is perfect for colony screening in the early stages of the reprogramming procedure. It can also be employed as a negative selection method to spot undifferentiated cells in advanced phases.
The Contract Research Organizations Category Witnessed Growth At A Rapid Rate.
The contract research organizations category dominated the market in 2021 due to the expanding emphasis on stem cell cytology and pathophysiology research and the expansion of public-private funding to assist the development and commercialization of stem cell products. A corporation that supports the pharmaceutical, biotechnology, and medical device sectors by contracting out research activities is known as a contract research organization (CRO). A CRO might offer commercialization, clinical trial management, pharmacovigilance, clinical development, outcomes research, and real-world evidence, among other services.
The North American iPSC Characterization Kit Market Holds A Signification Revenue Share.
The North American iPSC characterization kit market is expected to register the highest market share. Vital industry players are well represented in the area, and significant private and public financing for research institutes is a key factor in this situation. In addition, developing the iPSC characterization kit market is aided by a robust infrastructure for R&D and application scenarios, including tissue engineering and toxicity screening. It is projected that the region will maintain its dominance. In addition, Asia Pacific is projected to increase in the global iPSC characterization kit market. Induced pluripotent stem cell use is anticipated to be fueled by substantial market expansion in nations like Japan and China, as well as growing interest in regenerative medicine in the area, which will further fuel the growth of the iPSC characterization kit market. Although there isn't a clear legislative framework for the iPSC business, regional governments are making concerted attempts to change that. Those efforts are anticipated to support the development of the iPSC characterization kit market.
Recent Developments:
- In August 2021, Fate Therapeutics officially declared that FT819 had been successful in treating its first patient in a clinical trial. FT819, which is a CAR-T cell treatment, was made utilizing iPSCs.
- In May 2022, Sernova and Evotec discussed a strategic treaty to develop an IPSC-based beta substitute therapy for type 1 and 2 diabetes.
- In July 2021, SCM Lifescience Co. Ltd., a South Korea-based cell therapy developing firm, pronounced that it had in-license a diabetes drug from Allele Biotechnology and Pharmaceuticals, Inc., which is a pancreatic beta cell therapy extracted from IPSCs, and the deal has been signed at a valuation of US$ 0.75 million.
iPSC Characterization Kit Market Report Scope
|
Report Attribute |
Specifications |
|
Growth Rate CAGR |
CAGR of 15.54 % from 2024 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Million and CAGR from 2024 to 2031 |
|
Historic Year |
2019 to 2023 |
|
Forecast Year |
2024-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
Type, Application |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ;The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia |
|
Competitive Landscape |
Merck KGaA, Takara Bio, Thermo Fisher Scientific, BD Biosciences, Applied StemCell, Amsbio, Bio-Techne, ALSTEM, STEMCELL Technologies, System Biosciences, Applied Biological Materials, Creative Bioarray, Elixirgen Scientific and Miltenyi Biotec. |
|
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
